BUZZ-Valeant Pharmaceuticals: Estimates strong Q3 results
** Canadian drugmaker's shares up about 5.4 pct at C$135.15
** Company's U.S.-listed shares up about 5 percent at $121.71
** Says it estimates Q3 revenue above Street expectations
** Says expects overall Q3 same-store organic growth to be more than 15 pct
** Says adjusted profit to come in above its own forecast
** Up to Tuesday's close of C$128.29, company's Toronto-listed shares had fallen nearly 8 percent since April 21, when Valeant teamed up with activist-investor William Ackman to buy botox-maker Allergan Inc
© Thomson Reuters 2017 All rights reserved.